# The Efficacy of Transarterial Chemoinfusion (TAI) Combine Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC)

> **NCT03851887** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 33 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **COMBINATION_PRODUCT:** TAI combine SBRT

## Key facts

- **NCT ID:** NCT03851887
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-01
- **Primary completion:** 2020-01-31
- **Final completion:** 2022-01-31
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2019-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03851887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03851887, "The Efficacy of Transarterial Chemoinfusion (TAI) Combine Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT03851887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*